Evidence map›Paper›PMID 41898501›Full record

ArticleInternational journal of molecular sciences2026

Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in

Anna Nagel, Ethan W Hass, Hollie Hayes, Lenna Huelbes, Sofia Oliveira, Haley M Hardin, Mikhail Marasigan, Eric Nisenbaum, Carly Misztal, Fred F Telischi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna NagelBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Ethan W HassBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Hollie HayesBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Lenna HuelbesBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Sofia OliveiraBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Haley M HardinBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.
Mikhail MarasiganDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Eric NisenbaumDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Carly MisztalDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Fred F TelischiDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Michael E IvanDepartment of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0002-4798-4989
Xue-Zhong LiuDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0002-4758-6470
Olena R BrachoDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Christine T DinhDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Cristina Fernandez-ValleBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.

Funding

Preclinical Testing of PI3K Inhibitors for Vestibular SchwannomasR01DC017264 · NIDCD · UNIVERSITY OF CENTRAL FLORIDA · PI FERNANDEZ-VALLE, CRISTINA MARIA, LIU, XUE Z · 2018 to 2022
$3.1M
Tumor-Mediated Hearing Loss in Neurofibromatosis Type IIK08DC017508 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DINH, CHRISTINE THUYVAN · 2019 to 2023
$840k
Interdisciplinary Research Training in OtolaryngologyT32DC015995 · NIDCD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, XUE Z · 2018 to 2022
$330k
Children's Tumor Foundation 2024-01-005NIDCD NIH HHS K08DC017508NIDCD NIH HHS R01DC017264NIDCD NIH HHS T32DC015995
6 · The paper itself

Abstract

There is no approved drug therapy for schwannomas associated with

Indexed as

ApoptosisCytokinesHydroxamic AcidsNeurilemmomaNeurofibromin 2AnimalsAntineoplastic AgentsCell Line, TumorHistone Deacetylase InhibitorsHumansMorpholinesPyrimidinesSignal TransductionSulfur CompoundsAntineoplastic AgentsCUDC-907CytokinesfimepinostatHistone Deacetylase InhibitorsHydroxamic AcidsMorpholinesNeurofibromin 2PyrimidinesSulfur CompoundsCUDC-907fimepinostatHDAChistone deacetylase inhibitorNeurofibromatosis Type 2NF-κBschwannomatumor necrosis factor receptor

Identifiers

PMID41898501
PMCPMC13026985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.